Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and other major diseases, announces that the first patient with diabetic macular edema (DME) has been successfully dosed in the Phase 1 study of IBI324, a potential first-in-class ophthalmic recombinant human anti-VEGF-A and anti-Ang-2 bispecific antibody.

This Phase 1 dose escalations study (CTR20221524) aims to examine the safety and tolerability of intravitreal injection of IBI324 in subjects with diabetic macular edema (DME). IBI324 is a dual-target specific recombinant fully humanized anti-VEGF-A and anti-Ang-2 bispecific antibody developed by Innovent, which can achieve anti-angiogenesis, vascular stabilization, and inflammation inhibition by blocking both VEGF-A and Ang-2, aiming to bring more potential clinical benefits to DME patients, such as prolonging the dosing interval and improving treatment compliance.

Read more here